Vizimpro (dacomitinib) – to treat adults patients with non small cell lung cancer (NSCLC) when the disease is advanced or has spread.
Vizimpro contains the active substance dacomitinib, which belongs to a group of medicines called protein tyrosine kinase inhibitors which are used to treat cancer. Vizimpro is used to treat adults with a type of lung cancer called ‘non-small cell lung cancer’. If a test has shown that your cancer has certain changes (mutations) in a gene called ‘EGFR’ (epidermal growth factor receptor) and has spread to your other lung or other organs, your cancer is likely to respond to treatment with Vizimpro. Vizimpro can be used as your first treatment once your lung cancer has spread to your other lung or
NAME OF THE MEDICINAL PRODUCT
Vizimpro 15 mg film-coated tablets
Vizimpro 30 mg film-coated tablets
Vizimpro 45 mg film-coated tablets
STATEMENT OF ACTIVE SUBSTANCE(S)
Each film-coated tablet contains 15 mg dacomitinib (as dacomitinib monohydrate).
Each film-coated tablet contains 30 mg dacomitinib (as dacomitinib monohydrate).
Each film-coated tablet contains 45 mg dacomitinib (as dacomitinib monohydrate).
30 film-coated tablets
METHOD AND ROUTE(S) OF ADMINISTRATION